NRG1 and pancreatic ductal adenocarcinoma: The FDA recently granted accelerated approval in December 2024 for zenocutuzumab, a bispecific antibody targeting HER3-mediated NRG1 signaling, as the first therapy specifically for NRG1 fusion-positive advanced NSCLC and pancreatic ductal adenocarcinoma (PDAC).